Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers.

Trial Profile

Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Sponsors IRIS
  • Most Recent Events

    • 01 Mar 2012 Status changed from recruiting to completed as reported by ISRCTN.
    • 12 May 2011 Planned end date changed from 30 Sep 2011 to 29 Feb 2012 as reported by ISRCTN.
    • 03 Dec 2010 Planned end date (30 Sep 2011) added as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top